次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

印刷用表示 |テキストサイズ　小 |中 |大 |

LinkIconHOME
LinkIcon市場調査レポート
LinkIconカスタムリサーチ
LinkIconニュース配信
LinkIcon会社概要
LinkIconLink

コンパニオン診断の世界市場：2024年に至る技術別、診断領域別予測

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024

出版元：MarketsandMarketsLinkIcon出版元について
発行年：2019年9月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文240ページになります。
商品コード：MAM1681

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
コンパニオン診断の世界市場規模は今後2024年段階では73億ドルに達すると予測されます。2019年の同市場規模は35億ドルと推計され、2019～2024年の平均年成長率は15.7%増で推移するとレポートでは分析しています。当レポートでは、2024年に至るコンパニオン診断の世界市場予測(市場規模US$)、製品/サービス別市場(アッセイキット/試薬、ソフトウェア/サービス)、技術別市場(PCR、NGS、ISH、IHC、その他)、診断領域別市場(がん各種、神経疾患、感染症、心血管疾患、その他)、エンドユーザー別市場(製薬/バイオ医薬品企業、リファレンスラボ、CRO、その他)、主要国地域別市場など、各種の予測データに基づき市場を展望しています。また市場動向、競合状況、主要企業プロフィールなどの分析も交えて、概略以下の構成でお届けいたします。

【レポート構成概要】
◆コンパニオン診断の世界市場予測2017-2024年
・市場規模(US$)

◆製品/サービス別、市場-2024年
・アッセイキット/試薬
・ソフトウェア/サービス
※(市場規模US$)

◆技術別、市場-2024年
・ポリメラーゼ連鎖反応(PCR)
・次世代シーケンス(NGS)
・In situ ハイブリダイゼーション(ISH) 
・免疫組織化学(IHC)
・その他
※(市場規模US$)

◆診断領域別、市場-2024年
がん
・乳がん
・肺がん
・大腸がん
・メラノーマ
・胃がん
神経疾患
感染症
心血管疾患
その他
※(市場規模US$)

◆エンドユーザー別、市場-2024年
・製薬/バイオ医薬品企業
・リファレンスラボ
・医薬品開発業務受託機関(CRO)
・その他
※(市場規模US$)

◆主要国地域別市場-2024年
北米
・米国、カナダ
欧州
・ドイツ、英国、スイス、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド、オーストラリア
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
※国地域別に全てのセグメントの細分化データ掲載、詳細は目次参照
※(市場規模US$)

◆市場分析
・市場ダイナミクス（ドライバー、障壁、機会、課題）
・当局規制
・競合状況

◆コンパニオン診断の主要企業プロフィール動向
・F. HOFFMANN-LA ROCHE AG
・AGILENT TECHNOLOGIES, INC.
・QIAGEN N.V.
・ABBOTT LABORATORIES, INC.
・ALMAC GROUP
・DANAHER CORPORATION
・ILLUMINA INC.
・BIOMÉRIEUX SA
・MYRIAD GENETICS, INC.
・シスメックス株式会社
・THERMO FISHER SCIENTIFIC, INC.
・ABNOVA CORPORATION
・GUARDANT HEALTH, INC.

（全240頁）


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.3            MARKET SCOPE
1.3.1               MARKETS COVERED.. 22
1.3.2               YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            LIMITATIONS
1.6            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.1.1               SECONDARY DATA
2.1.1.1             KEY DATA FROM SECONDARY SOURCES
2.1.2               PRIMARY DATA
2.1.2.1             KEY DATA FROM PRIMARY SOURCES
2.1.2.2             KEY INDUSTRY INSIGHTS
2.2            MARKET SIZE ESTIMATION
2.3            MARKET BREAKDOWN AND DATA TRIANGULATION
2.4            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            COMPANION DIAGNOSTICS: MARKET OVERVIEW.. 39
4.2            ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2018)
4.3            REGIONAL MIX: COMPANION DIAGNOSTICS MARKET
4.4            COMPANION DIAGNOSTICS MARKET: DEVELOPING VS. DEVELOPED COUNTRIES
4.5            GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1               DRIVERS
5.2.1.1             ADVANTAGES OF COMPANION DIAGNOSTICS
5.2.1.2             GROWING NEED FOR TARGETED THERAPY
5.2.1.3             GROWING IMPORTANCE OF PERSONALIZED MEDICINE
5.2.1.4             INCREASING GLOBAL INCIDENCE OF CANCER
5.2.1.5             GROWING APPLICATION AREAS OF COMPANION DIAGNOSTICS
5.2.2               RESTRAINTS
5.2.2.1             HIGH COST OF COMPANION DIAGNOSTIC TESTS
5.2.2.2             UNCERTAIN REIMBURSEMENT SCENARIO IN DIFFERENT REGIONS
5.2.3               OPPORTUNITIES
5.2.3.1             INCREASING DEMAND FOR NEXT-GENERATION SEQUENCING
5.2.3.2             GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS IN DRUG DEVELOPMENT
5.2.3.3             INCREASING NUMBER OF CLINICAL TRIALS
5.2.4               CHALLENGES
5.2.4.1             SHORTAGE OF TRAINED PROFESSIONALS

6.... INDUSTRY INSIGHTS

6.1            INTRODUCTION
6.2            INDUSTRY TRENDS
6.2.1               GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS
6.2.2               INCREASING COLLABORATIONS
6.3            REGULATORY ANALYSIS
6.3.1               NORTH AMERICA
6.3.1.1             US
6.3.1.2             CANADA
6.3.2               EUROPE
6.3.3               ASIA PACIFIC
6.3.3.1             AUSTRALIA
6.3.3.2             JAPAN
6.3.3.3             CHINA
6.3.3.4             INDIA
6.3.4               BRAZIL
6.4            PRODUCT PIPELINE ANALYSIS

7.... COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

7.1            INTRODUCTION
7.2            ASSAYS, KITS, & REAGENTS
7.2.1               THE VOLUME OF CDX TESTS PERFORMED IN LABORATORIES IS INCREASING, WHICH SUPPORTS THE ADOPTION OF ASSAYS & KITS
7.3            SOFTWARE & SERVICES
7.3.1               THE NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES IS INCREASING, CONTRIBUTING TO THE GROWTH OF
THE COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET. 66

8.... COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

8.1            INTRODUCTION
8.2            POLYMERASE CHAIN REACTION (PCR)
8.2.1               GROWING APPLICATIONS OF PCR TECHNOLOGIES IN THE FIELD OF PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS DRIVE
THE GROWTH OF THIS SEGMENT
8.3            NEXT-GENERATION SEQUENCING (NGS)
8.3.1               THE NGS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
8.4            IN SITU HYBRIDIZATION (ISH)
8.4.1               INCREASING ADOPTION OF ISH IS MAINLY DUE TO ADVANCEMENTS IN HYBRIDIZATION AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS
8.5            IMMUNOHISTOCHEMISTRY (IHC)
8.5.1               INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN COMPANION DIAGNOSTICS TO DRIVE
THE GROWTH OF THIS SEGMENT
8.6            OTHER TECHNOLOGIES

9.... COMPANION DIAGNOSTICS MARKET, BY IN4DICATION

9.1            INTRODUCTION
9.2            CANCER
9.2.1               BREAST CANCER
9.2.1.1             BREAST CANCER IS THE MOST COMMON CANCER AMONG WOMEN—A KEY FACTOR CONTRIBUTING TO THE LARGE SHARE OF THIS MARKET SEGMENT
9.2.2               LUNG CANCER
9.2.2.1             GROWING DEMAND FOR THERAPEUTIC DRUGS AND THEIR HIGH EFFICACY IN
THE TREATMENT OF LUNG CANCER INCREASE THE ADOPTION OF COMPANION DIAGNOSTICS IN THIS SEGMENT
9.2.3               COLORECTAL CANCER. 87
9.2.3.1             GROWING NEED FOR MOLECULAR PROFILING OF PRIMARY TUMORS IN COLORECTAL CANCER TO DRIVE GROWTH IN THIS MARKET SEGMENT
9.2.4               MELANOMA
9.2.4.1             GROWING INCIDENCE OF MELANOMA, ALONG WITH THE NEED FOR THE EARLY DIAGNOSIS OF GENETIC-MUTATED TUMORS, DRIVES THE DEMAND FOR COMPANION DIAGNOSTICS
9.2.5               GASTRIC CANCER
9.2.5.1             INCREASING FOCUS OF MARKET PLAYERS ON THE DEVELOPMENT OF TESTS AND KITS FOR GASTRIC CANCER INDICATIONS TO DRIVE MARKET GROWTH
9.3            NEUROLOGICAL DISEASES
9.3.1               GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS IN THIS SEGMENT
9.4            INFECTIOUS DISEASES
9.4.1               GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT DURING
THE FORECAST PERIOD
9.5            CARDIOVASCULAR DISEASES
9.5.1               GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE AND MORTALITY RATE OF CARDIOVASCULAR DISEASES TO DRIVE
GROWTH IN THIS SEGMENT
9.6            OTHER INDICATIONS

10.. COMPANION DIAGNOSTICS MARKET, BY END USER

10.1          INTRODUCTION
10.2          PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1             WIDE USAGE OF COMPANION DIAGNOSTICS IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES OWING TO THEIR GROWING PROMINENCE IN DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
10.3          REFERENCE LABORATORIES
10.3.1             GROWING INCIDENCE OF DISEASES SUCH AS CANCER AND THE RISING DEMAND FOR TARGETED THERAPIES TO DRIVE THE GROWTH OF
THIS END-USER SEGMENT
10.4          CONTRACT RESEARCH ORGANIZATIONS
10.4.1             CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES RANGING FROM COMPANION DIAGNOSTIC DEVELOPMENT TO TARGETED THERAPY-RELATED CLINICAL TRIALS
10.5          OTHER END USERS

11.. COMPANION DIAGNOSTICS MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1             US
11.2.1.1           THE US IS THE LARGEST MARKET FOR COMPANION DIAGNOSTICS
IN NORTH AMERICA
11.2.2             CANADA
11.2.2.1           GOVERNMENT INITIATIVES TO PROMOTE COMPANION DIAGNOSTICS IN VARIOUS INDICATIONS ARE EXPECTED TO DRIVE MARKET GROWTH IN CANADA
11.3          EUROPE
11.3.1             GERMANY
11.3.1.1           GERMANY IS A MAJOR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY PRODUCTS IN EUROPE
11.3.2             UK
11.3.2.1           GROWTH IN THE COUNTRY’S LIFE SCIENCE INDUSTRY AND INCREASING RESEARCH ARE KEY FACTORS DRIVING MARKET GROWTH IN THE UK
11.3.3             SWITZERLAND
11.3.3.1           SWITZERLAND BOASTS A STRONG RESEARCH-ORIENTED PHARMA INDUSTRY, A KEY FACTOR SUPPORTING MARKET GROWTH
11.3.4             FRANCE
11.3.4.1           INCREASING GOVERNMENT FUNDING FOR GENOMICS AND PERSONALIZED THERAPEUTICS R&D IS DRIVING MARKET GROWTH
11.3.5             ITALY
11.3.5.1           GROWING DISEASE PREVALENCE HAS CONTRIBUTED TO THE DEMAND FOR BETTER, MORE POWERFUL THERAPEUTICS IN ITALY
11.3.6             SPAIN
11.3.6.1           MEDICAL INSTITUTES IN SPAIN ARE INCREASINGLY FOCUSING ON CANCER BIOMARKER RESEARCH
11.3.7             REST OF EUROPE
11.4          ASIA PACIFIC
11.4.1             JAPAN
11.4.1.1           JAPAN HOLDS THE LARGEST SHARE OF THE MARKET IN APAC
11.4.2             CHINA
11.4.2.1           CHINA IS ONE OF THE MOST PROMINENT RESEARCH MARKETS, WORLDWIDE
11.4.3             INDIA
11.4.3.1           INITIATIVES BY THE INDIAN GOVERNMENT TO TACKLE THE GROWING BURDEN OF CANCER ARE EXPECTED TO INCREASE THE ADOPTION OF COMPANION DIAGNOSTICS IN THE COUNTRY
11.4.4             AUSTRALIA
11.4.4.1           GROWING GERIATRIC POPULATION IN AUSTRALIA HAS RESULTED IN INITIATIVES TO ENHANCE HEALTHCARE ACCESS AND INFRASTRUCTURE
11.4.5             REST OF ASIA PACIFIC
11.5          LATIN AMERICA
11.5.1             BRAZIL
11.5.1.1           BRAZIL DOMINATES THE LATIN AMERICAN COMPANION DIAGNOSTICS MARKET
11.5.2             MEXICO
11.5.2.1           MEXICO IS EMERGING AS A PROMINENT MEDICAL TOURISM HUB
11.5.3             REST OF LATIN AMERICA
11.6          MIDDLE EAST & AFRICA
11.6.1             RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          MARKET SHARE ANALYSIS
12.3          COMPETITIVE LEADERSHIP MAPPING, 2018. 189
12.4          VENDOR INCLUSION CRITERIA
12.5          VENDOR DIVE
12.5.1             VISIONARY LEADERS. 190
12.5.2             INNOVATORS
12.5.3             EMERGING COMPANIES
12.5.4             DYNAMIC DIFFERENTIATORS
12.6          COMPETITIVE SITUATIONS AND TRENDS
12.6.1             PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
12.6.2             ACQUISITIONS

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS AND SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1          F. HOFFMANN-LA ROCHE AG
13.2          AGILENT TECHNOLOGIES, INC.
13.3          QIAGEN N.V.
13.4          ABBOTT LABORATORIES, INC.
13.5          ALMAC GROUP
13.6          DANAHER CORPORATION
13.7          ILLUMINA INC.
13.8          BIOMÉRIEUX SA
13.9          MYRIAD GENETICS, INC.
13.10       SYSMEX CORPORATION
13.11       THERMO FISHER SCIENTIFIC, INC.
13.12       ABNOVA CORPORATION
13.13       GUARDANT HEALTH, INC.
*BUSINESS OVERVIEW, PRODUCTS AND SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14             APPENDIX

 

LIST OF TABLES

TABLE 1               STANDARD CURRENCY CONVERSION RATES
TABLE 2               COMPANION DIAGNOSTICS MARKET SNAPSHOT, 2019 VS. 2024
TABLE 3               COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
TABLE 4               PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
TABLE 5               LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
TABLE 6               RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET
TABLE 7               US: CLASSIFICATION OF MEDICAL DEVICES
TABLE 8               JAPAN: CLASSIFICATION OF MEDICAL DEVICES
TABLE 9               CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 10             INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 11             COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS,
BY MARKET PLAYER: CURRENT MARKET SCENARIO
TABLE 12             COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 13             COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, & REAGENTS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 14             COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15             COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 16             COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION
TABLE 17             MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET
TABLE 18             COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19             MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET
TABLE 20             COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21             MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET
TABLE 22             COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 23             MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET
TABLE 24             COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25             COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26             COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 27             COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 28             COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 29             COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 30             COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 31             COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32             COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33             COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 34             COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35             COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36             COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37             COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 38             COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 39             COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40             COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41             COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42             COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 43             COMPANION DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 44             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 45             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 46             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 47             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 48             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 49             NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 50             US: KEY MACROINDICATORS
TABLE 51             US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 52             US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 53             US: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 54             US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 55             US: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 56             CANADA: KEY MACROINDICATORS
TABLE 57             CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 58             CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 59             CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 60             CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 61             CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 62             EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 63             EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 64             EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 65             EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 66             EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 67             EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 68             GERMANY: KEY MACROINDICATORS
TABLE 69             GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 70             GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 71             GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 72             GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 73             GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 74             UK: KEY MACROINDICATORS
TABLE 75             UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 76             UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 77             UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 78             UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 79             UK: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 80             SWITZERLAND: KEY MACROINDICATORS
TABLE 81             SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 82             SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 83             SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 84             SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 85             SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 86             FRANCE: KEY MACROINDICATORS
TABLE 87             FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 88             FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 89             FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 90             FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 91             FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 92             ITALY: KEY MACROINDICATORS
TABLE 93             ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 94             ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 95             ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 96             ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 97             ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 98             SPAIN: KEY MACROINDICATORS
TABLE 99             SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 100          SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 101          SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 102          SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 103          SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 104          ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 105          ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 106          ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 107          ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 108          ROE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 109          APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 110          APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 111          APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 112          APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 113          APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 114          APAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 115          JAPAN: KEY MACROINDICATORS
TABLE 116          JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 117          JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 118          JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 119          JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 120          JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 121          CHINA: KEY MACROINDICATORS
TABLE 122          CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 123          CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 124          CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 125          CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 126          CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 127          INDIA: KEY MACROINDICATORS
TABLE 128          INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 129          INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 130          INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 131          INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 132          INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 133          AUSTRALIA: KEY MACROINDICATORS
TABLE 134          AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 135          AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 136          AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 137          AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 138          AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 139          ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 140          ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 141          ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 142          ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 143          ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 144          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 145          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION)
TABLE 146          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 147          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 148          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2024 (USD MILLION)
TABLE 149          LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 150          BRAZIL: KEY MACROINDICATORS
TABLE 151          BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 152          BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 153          BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 154          BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 155          BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 156          MEXICO: KEY MACROINDICATORS
TABLE 157          MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 158          MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 159          MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 160          MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 161          MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 162          ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 163          ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 164          ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 165          ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 166          ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 167          MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION)
TABLE 168          MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 169          MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 170          MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2024 (USD MILLION)
TABLE 171          MEA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 172          GROWTH STRATEGY MATRIX (2016–2019)
TABLE 173          PRODUCT LAUNCHES & APPROVALS, 2016–2019
TABLE 174          PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS, 2016–2019
TABLE 175          ACQUISITIONS, 2016–2019
TABLE 176          EXPANSIONS, 2016-2019

 

LIST OF FIGURES

FIGURE 1             RESEARCH DESIGN
FIGURE 2             PRIMARY SOURCES
FIGURE 3             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4             MARKET SIZE APPROACH
FIGURE 5             TOP-DOWN APPROACH
FIGURE 6             DATA TRIANGULATION METHODOLOGY
FIGURE 7             COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019 VS. 2024 (USD MILLION)
FIGURE 8             COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION)
FIGURE 9             COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2019 VS. 2024 (USD MILLION)
FIGURE 10          COMPANION DIAGNOSTICS MARKET, BY END USER,
2019 VS. 2024 (USD MILLION)
FIGURE 11          GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET
FIGURE 12          INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY IS DRIVING MARKET GROWTH
FIGURE 13          PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2018
FIGURE 14          ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
FIGURE 15          DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD
FIGURE 16          CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 17          COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES
FIGURE 18          GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016
FIGURE 19          GLOBAL CANCER INCIDENCE, 2008–2030
FIGURE 20          PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION
DIAGNOSTIC PRODUCTS
FIGURE 21          INDIA: REGULATORY PROCESS FOR IVD DEVICES
FIGURE 22          ASSAYS, KITS, & REAGENTS TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 23          POLYMERASE CHAIN REACTION TO DOMINATE THE COMPANION DIAGNOSTICS TECHNOLOGY MARKET DURING THE FORECAST PERIOD
FIGURE 24          CANCER INDICATION SEGMENT TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 25          BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD
FIGURE 26          GLOBAL LUNG CANCER INCIDENCE, 2012–2030
FIGURE 27          PHARMACEUTICAL& BIOPHARMACEUTICAL COMPANIES TO DOMINATE
THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 28          GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 29          NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
FIGURE 30          EUROPE: COMPANION DIAGNOSTICS MARKET SNAPSHOT
FIGURE 31          ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
FIGURE 32          KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2016 AND MAY 2019
FIGURE 33          COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 34          COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2018
FIGURE 35          PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2016 & 2019
FIGURE 36          F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 37          AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 38          QIAGEN N.V.: COMPANY SNAPSHOT
FIGURE 39          ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 40          DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 41          ILLUMINA INC.: COMPANY SNAPSHOT
FIGURE 42          BIOMÉRIEUX SA: COMPANY SNAPSHOT
FIGURE 43          MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
FIGURE 44          SYSMEX CORPORATION: COMPANY SNAPSHOT
FIGURE 45          THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 46          GUARDANT HEALTH, INC.: COMPANY SNAPSHOT


掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

▲　ページトップへ

LinkIconリサーチカテゴリ一覧
LinkIconスマートグリッド
LinkIcon電池・燃料電池・蓄電池
LinkIcon再生可能エネルギー
LinkIcon天然資源・エネルギー
LinkIconマテリアル
LinkIcon水処理・水資源
LinkIcon航空宇宙・防衛セキュリティ
LinkIcon自動車・各種車両
LinkIcon通信・IT
LinkIcon消費財・食品飲料
LinkIcon医療・医薬品・ヘルスケア
LinkIcon電気・エレクトロニクス
LinkIcon産業機械、マシナリー

関連レポート

LinkIconがんプロファイリングの世界市場：技術別、がんタイプ別2024年予測

LinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
（ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません）

お問い合わせ

LinkIconお問合わせはこちらから

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。


milk_btn_pagetop.png

since 2009-08-17 / Copyright 2016 ResearchStation, LLC. All Rights Reserved.